Idera Pharmaceuticals News
Idera Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2013.
Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque PsoriasisBusiness Wire May 8
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andMay 2
Idera Pharmaceuticals today announced the pricing of an underwritten public offering by Idera Pharmaceuticals of for a combined public offering price of $0.50 per share of common stock and related warrant, 17,500,000 shares of common stock and related warrants to purchase up to 17,500,000 shares of common stock at an exercise price of $0.47 per share, and for a combined public offering price of $0.49 ...